Anteris Technologies Global Corp. Common Stock (AVR) Stock Price
AVRStock
$6.05+21.98%52W
Market Cap$588.92M
P/E—
PEG Ratio—
Div yield—
Beta1.75
AVR Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-13.72%
Price vs S&P 500 (4W)-24.44%
VGM Score40.79
AVR Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.21 | -$0.30 | -45.16%(-$0.09) | |
| Q4 2025 | -$0.56 | -$0.75 | -33.93%(-$0.19) | |
| Q3 2025 | -$0.57 | -$0.62 | -7.83%(-$0.05) | |
| Q2 2025 | -$0.48 | -$0.58 | -20.77%(-$0.10) |
AVR Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.00
4.00
4.00
4.00
Industry Peers — Orthopedic & Prosthetic Devices(31)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
AVRAnteris Technologies Global Corp. Common Stock | D | C | C | 263.0x | — | 75.0% | -4738.4% | $6.05 |
| ISRGIntuitive Surgical Inc. | D | B | B | 13.7x | 18.2% | 66.7% | 31.3% | $426.70 |
| EWEdwards Lifesciences Corp | D | C | B | 7.7x | 6.7% | 77.8% | 18.2% | $86.60 |
| STESTERIS plc | C | C | B | 3.6x | 13.8% | 44.4% | 18.9% | $222.66 |
| ZBHZimmer Biomet Holdings, Inc. | B | C | B | 2.1x | 3.2% | 69.9% | 14.2% | $94.98 |
| SNNSmith & Nephew plc | B | C | C | 1.9x | 6.2% | 68.2% | 12.9% | $29.06 |
| ALGNAlign Technology Inc | B | D | C | 2.5x | 10.3% | 69.0% | 13.2% | $147.31 |
| MSAMine Safety Incorporated | C | C | B | 3.5x | 6.8% | 47.6% | 21.2% | $179.05 |
| ESTAEstablishment Labs Holdings Inc. | F | A | C | 7.2x | 20.0% | 70.5% | -7.6% | $59.18 |
| ENOVEnovis Corporation | B | D | C | 0.5x | -6.0% | 61.4% | -45.1% | $19.59 |
| CDRECadre Holdings, Inc. | B | C | C | 1.6x | 8.6% | 41.8% | 10.1% | $26.38 |
About Anteris Technologies Global Corp. Common Stock
Anteris Technologies Global Corp develops minimally invasive medical devices for structural heart disease, with its DurAVR Transcatheter Heart Valve as the flagship product. The balloon-expandable valve treats aortic stenosis through a biomimetic design that mimics the performance of a healthy human aortic valve. The company operates primarily in the United States, with additional presence in Germany, Australia, Switzerland, and Sweden.